Antifungal activity of secondary metabolites produced by fungi

Abstract

Antifungal agents, which are essential for treating various body fungal infections, have evolved significantly since the late 19th century where local antiseptics had limited effectiveness. However, the discovery of penicillin in 1928 and the subsequent realization that it was ineffective against fungi spurred the development of specific antifungals. The discovery of amphotericin B in 1955, azoles in the 1960s, and echinocandins in the 1970s made key breakthroughs. To inhibit fungal growth, each class targets different fungal components, such as the cell membrane or cell wall. Soil, marine, and endophytic fungi can yield antifungals, each contributing unique compounds. Rising resistance challenges the sustainability of antifungal agents, necessitating advanced susceptibility testing and stewardship programs. Resistance mechanisms include genetic mutations, efflux pumps, and enzymatic modifications. In Egypt, studies reveal increasing resistance, emphasizing the need for comprehensive strategies to mitigate this tendency. This article provides a comprehensive analysis of the remarkable antifungal capabilities of fungi, emphasizing their capacity to generate unique and varied antimicrobial substances that effectively combat infections affecting humans, plants, and marine organisms. This also emphasizes the important role that fungi recovered from various environmental habitats may play in our fight against human pathogenic fungi. This serves as a reason to intensify our efforts to find new and powerful antimicrobial medications.